MarieLouise MD - Exscientia Interim Lead
| EXAIDelisted Stock | USD 4.84 0.15 3.20% |
Executive
MarieLouise MD is Interim Lead of Exscientia Ltd ADR
| Age | 60 |
| Phone | 44 18 6581 8941 |
| Web | https://www.exscientia.ai |
Exscientia Management Efficiency
The company has return on total asset (ROA) of (0.2122) % which means that it has lost $0.2122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4643) %, meaning that it created substantial loss on money invested by shareholders. Exscientia's management efficiency ratios could be used to measure how well Exscientia manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matthew Kinn | Recursion Pharmaceuticals | N/A | |
| MS MBA | PDS Biotechnology Corp | 58 | |
| Dennis Williams | Adaptimmune Therapeutics Plc | N/A | |
| Jonae Barnes | Atea Pharmaceuticals | N/A | |
| XiaoJian Zhou | Atea Pharmaceuticals | N/A | |
| David Brady | Zura Bio Limited | N/A | |
| Mahesh Padval | Relay Therapeutics | N/A | |
| Jayanthi Wolf | Atea Pharmaceuticals | N/A | |
| Ariyapadi Krishnaraj | Atea Pharmaceuticals | N/A | |
| Candice Masse | Elevation Oncology | N/A | |
| Snehal Patel | Sana Biotechnology | N/A | |
| Michael Naso | Century Therapeutics | N/A | |
| Debra DursoBumpus | Blueprint Medicines Corp | 54 | |
| Kirk MD | PDS Biotechnology Corp | 72 | |
| Michael Howell | Zura Bio Limited | 47 | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Deanne Randolph | PDS Biotechnology Corp | N/A | |
| Christian MBA | Sana Biotechnology | 41 | |
| Nancy Agrawal | Atea Pharmaceuticals | N/A | |
| BA ACA | Adaptimmune Therapeutics Plc | 54 | |
| Shane Olwill | Pieris Pharmaceuticals | 48 | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 |
Exscientia ADR Leadership Team
Elected by the shareholders, the Exscientia's board of directors comprises two types of representatives: Exscientia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Exscientia. The board's role is to monitor Exscientia's management team and ensure that shareholders' interests are well served. Exscientia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Exscientia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Overington, Chief Officer | ||
| Eileen JenningsBrown, Chief Officer | ||
| Ben AshwellFryer, VP Fin | ||
| Parker Moss, Executive Development | ||
| Ben Taylor, Chief CFO | ||
| CBE DPHIL, CEO Founder | ||
| Nikolaus Krall, Executive Medicine | ||
| Dan Ireland, Executive Secretary | ||
| Heather Togwell, Operations Mang | ||
| Caroline Rowland, Chief Officer | ||
| Chris Thomas, VP People | ||
| Garry Pairaudeau, Chief Officer | ||
| MarieLouise MD, Interim Lead | ||
| FRSE DPHIL, CEO Founder | ||
| David Hallett, Interim Officer | ||
| Michael MD, Chief Officer | ||
| Margo Mosley, VP Operations | ||
| Richard Law, Chief Officer | ||
| Sara Sherman, Vice Relations |
Exscientia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Exscientia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (10.66) % | ||||
| Current Valuation | 346.92 M | ||||
| Shares Outstanding | 130.82 M | ||||
| Shares Owned By Insiders | 25.90 % | ||||
| Shares Owned By Institutions | 20.80 % | ||||
| Number Of Shares Shorted | 2.81 M | ||||
| Price To Book | 1.95 X | ||||
| Price To Sales | 37.10 X |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exscientia Ltd ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Exscientia Stock
If you are still planning to invest in Exscientia ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Exscientia's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |